Beijing Airdoc Technology Co (HKSE:02251) ROCE % : -10.70% (As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Beijing Airdoc Technology Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Beijing Airdoc Technology Co's annualized ROCE % for the quarter that ended in Jun. 2024 was -10.70%.

Beijing Airdoc Technology Co ROCE % Historical Data

The historical data trend for Beijing Airdoc Technology Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beijing Airdoc Technology Co ROCE % Chart

Beijing Airdoc Technology Co Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROCE %

Get a 7-Day Free Trial

-60.16

-12.81

-9.92

-8.85

-18.50

Beijing Airdoc Technology Co Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
ROCE %	Get a 7-Day Free Trial						-9.45	-4.74	-12.90	-10.70	-26.69

Beijing Airdoc Technology Co ROCE % Calculation

Beijing Airdoc Technology Co's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-158.941	/	( ( (1943.033 - 72.212)	+	(1842.921 - 120.575) )	/ 2 )
	=	-158.941	/	( (1870.821	+	1722.346)	/ 2 )
	=	-158.941	/	1796.5835
	=	-8.85 %

Beijing Airdoc Technology Co's ROCE % of for the quarter that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	-177.66	/	( ( (1842.921 - 120.575)	+	(1665.81 - 66.521) )	/ 2 )
	=	-177.66	/	( ( 1722.346	+	1599.289 )	/ 2 )
	=	-177.66	/	1660.8175
	=	-10.70 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

Beijing Airdoc Technology Co (HKSE:02251) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Beijing Airdoc Technology Co ROCE % Related Terms

Thank you for viewing the detailed overview of Beijing Airdoc Technology Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Beijing Airdoc Technology Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Beijing Airdoc Technology Co Ltd (HKSE:02251) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

West Third Ring North Road, Room 21, 4th Floor, Building 2, A2 Yard, Haidian District, Beijing, CHN, 100089

Website

https://www.airdoc.com

Beijing Airdoc Technology Co Ltd provides AI-empowered retina-based early detection, diagnosis, and health risk assessment solutions in China. Leveraging retinal imaging, multimodal data analyses, and AI deep learning algorithms, the company's solution differs from traditional chronic disease early detection and diagnosis, enabling non-invasive, accurate, fast, effective, and scalable detection and diagnosis of chronic diseases in both medical institutions and consumer healthcare providers. The Company derives revenue principally from the provision of AI-based software solutions, sales of hardware devices, and other services.

Executives

Lake Bleu Capital (hong Kong) Limited	2102 Investment manager
Zhang Dalei	2501 Other
Boci Trustee (hong Kong) Limited	2301 Trustee
Mialkos Tomasz Jakub	2101 Beneficial owner
Chen Mingqiang	2501 Other
Gao Fei	2501 Other
Yadong Beichen Venture Investment Co., Ltd.	2101 Beneficial owner
Shanghai Ruikun Venture Capital Investment Co., Ltd.	2201 Interest of corporation controlled by you
Shanghai Fosun Industrial Investment Co., Ltd.	2201 Interest of corporation controlled by you
Shanghai Fosun High Technology (group) Co., Ltd.	2201 Interest of corporation controlled by you
Guo Guangchang	2201 Interest of corporation controlled by you
Fosun International Limited	2201 Interest of corporation controlled by you
Fosun International Holdings Ltd.	2201 Interest of corporation controlled by you
Fosun Holdings Limited	2201 Interest of corporation controlled by you
Niagara Falls Holding Limited	2101 Beneficial owner

Beijing Airdoc Technology Co Headlines

No Headlines